Indefinite delivery indefinite quantity (IDIQ) for the procurement of erlotinib tablets in support of the U.S. Department of health and human services (dhhs), national institutes of health (NIH),…
Ended Indefinite Delivery Contract Awarded Last action
- Contract number
- 75N91020D00003
- Awardee
-
ASE Direct, Inc. UEI EZDFY7PVHWL4
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Task orders
- 5 $5,211,022 obligated
Award facts
- Opportunity
-
- Brand Name or Equal Tarceva (erlotinib hydrochloride) Tablets Solicitation · 75N91020Q00004 · Posted Dec 18, 2019
- Combined order value
- $5,211,022 Current and potential, with all options
- Last date to order 100% complete
- IDV ceiling 78% used
- $6,644,110.00
- Award type
- Single award
- Who can order
- Only the awarding agency
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- Total Small Business
- Competition
- Competed under SAP · 5 offers Simplified Acquisition
- Pricing
- Firm Fixed Price
Award details come from SAM.gov/FPDS.
About this IDV
The National Institutes of Health National Cancer Institute awarded a single-award indefinite delivery/indefinite quantity contract to ASE Direct, Inc. to procure erlotinib hydrochloride tablets in support of cancer research efforts. The contract has a potential value of $6.6M over a three-year ordering period ending January 2023. ASE Direct will supply 25mg, 100mg, and 150mg tablet formulations of the cancer drug under firm fixed price delivery orders, with performance at its facility in Brentwood, Tennessee.
The original solicitation sought brand name or equivalent erlotinib tablets to support the Division of Cancer Treatment and Diagnosis Cancer Therapy Evaluation Program. It was set aside for total small business and anticipated multiple delivery orders over the three-year ordering period. The first delivery order awarded to ASE Direct valued at $3.1M includes 240 bottles of 25mg tablets, 240 bottles of 100mg tablets, and 400 bottles of 150mg tablets to be delivered by March 2020. Subsequent orders procure additional quantities of erlotinib tablets for delivery through January 2023 in support of the National Cancer Institute's research efforts.
Description
Indefinite delivery indefinite quantity (IDIQ) for the procurement of erlotinib tablets in support of the U.S. Department of health and human services (dhhs), national institutes of health (NIH), national cancer institute (NCI), division of cancer TR
Task orders
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $0 |
Quick answers
Who was awarded contract 75N91020D00003?
75N91020D00003 was awarded to ASE Direct, Inc. by National Cancer Institute (National Institutes of Health) on January 24, 2020.
How much is contract 75N91020D00003 worth?
Orders under 75N91020D00003 have obligated $5,211,022. 75N91020D00003's own ceiling is $6,644,110.
How many orders have been placed under contract 75N91020D00003?
5 orders have been placed under 75N91020D00003, the latest on August 11, 2021.
Who can order from contract 75N91020D00003?
75N91020D00003 is a single award indefinite delivery contract. Only the awarding agency can place orders on it.
Was contract 75N91020D00003 competed?
The extent of competition for 75N91020D00003 was competed under sap. The government received 5 offers. It was set aside: Total Small Business.
On GovTribe
See this IDV's full record
- Every order and transaction
- The awardee's other awards and teaming partners
- Similar IDVs and recompete opportunities
- Ask GovTribe AI about this IDV